GlassScriptPhysician profile
Seth Craig Tarras
NPI 1932140902
$1,468.95
in general payments reported to CMS, 2019-2025
14 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2021: $37.28 · 2022: $338 · 2023: $140 · 2024: $252 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $284.45 | 2019-2025 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $271.45 | 2019-2025 | Ultomiris |
| Argenx US, INC. | $267.46 | 2022-2025 | Vyvgart Hytrulo |
| Abbvie INC. | $262.20 | 2021-2025 | Botox |
| Ns Pharma, INC. | $79.19 | 2024 | Viltepso |
| Ucb, INC. | $74.34 | 2023-2024 | Rystiggo |
| Greenwich Biosciences, INC. | $55.18 | 2019-2021 | |
| Grifols Shared Services North America, INC. | $45.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.53 | 2025 | Hyqvia |
| C2n Diagnostics, LLC | $24.15 | 2025 | Precivityad2 |
| Biohaven Pharmaceutical Holding Company LTD. | $20.28 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.27 | 2022 | |
| Amgen INC. | $15.71 | 2019 | |
| Pfizer INC. | $15.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Tarras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.